Labcorp has acquired select assets of Invitae, a leading medical genetics company.
The acquisition expands Labcorp's specialty testing capabilities and the company's ability to utilize genetic data to improve clinical trials and treatment regimens in oncology and select rare diseases. By integrating Invitae's genetic testing technology with Labcorp's specialty testing capabilities, the company will offer a complete set of insights for each patient, from testing and diagnosis to treatment.
Analyst QuickTime: In April 2024 , Labcorp was selected as the winning bidder for select assets of Invitae for USD 239 million. This acquisition was expected to generate annual revenue of ~USD 275 million–300 million for Labcorp, most of which will come from specialty testing.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.